Information Provided By:
Fly News Breaks for March 15, 2019
Mar 15, 2019 | 05:06 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target for Tetraphase Pharmaceuticals to $4 from $6 after the launch of Xerava came in below his estimates. The analyst now forecast Xerava sales of $3.5M in 2019 and $10.5M in 2020. Further, Tetraphase will delay Xerava launch in Europe to focus on U.S. launch, the analyst tells investors in a post-earnings research note. He reiterates an Overweight rating on the shares.
News For TTPH From the Last 2 Days
There are no results for your query TTPH